Close Menu

Adaptive Biotechnologies

The immune sequencing firm also provided an update on the development of its ImmunoSeq Dx clinical product for detecting prior infection with SARS-CoV-2.

The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.

Of the 28 companies in the index, 22 firms saw their stock prices increase, while six firms' share prices decreased.

News items for the week of July 27, 2020. 

The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.

The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.

The firm withdrew its 2020 revenue guidance and missed Wall Street estimates for both revenues and earnings.

The immune sequencing firm has engaged the FDA in discussions over how to get regulatory approval for one test for several seemingly different diseases.

Aiming to improve patient access to critical drugs and tests, a group of legislators have started a caucus to shore up bipartisan support for personalized medicine.

Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.

Pages